MO-C2N-DIAGNOSTICS
C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.
C₂N executives say the investment reflects the two companies’ shared desire to scale up and provide broad access to its Precivity™ tests, which are innovative blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine Alzheimer’s disease pathology, and aid in medical management and treatment decisions.
The companies agree that Eisai’s investment will catalyze C₂N’s efforts to expand the availability, accessibility and use of high-performance blood biomarker tests for the early diagnosis of Alzheimer’s disease in the U.S.
Dr. Joel Braunstein, C₂N’s CEO, said, “We greatly appreciate the dedication and thoroughness Eisai brought to evaluating the value and quality of our advanced diagnostic solutions in the field of brain health. With this financing, we’re building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer’s disease through early detection and treatment and, ultimately, prevention. We’re proud to have Eisai’s leadership in the field as we’re transforming the management and clinical care standard for patients with Alzheimer’s disease. The availability of blood biomarkers that are closely correlated with gold standard measures, such as positron emission tomography (PET) scans, will improve accessibility for patients to obtain safe and effective drug treatments as more become available.”
“The field of highly accurate blood-based diagnostics is rapidly advancing and expanding,” said Keisuke Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai. “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease.”
C2N and Eisai initially announced in 2022 that they were working “to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment who are not currently participating in a clinical trial.”
About C2N Diagnostics, LLC
C₂N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C₂N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C₂N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C₂N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C₂N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation and Alzheimer’s Association. For more information visit www.C2N.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306427979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
Erbe introduces VIO® 3n & VIO® seal: Tailored electrosurgical generators for high-performance workflows25.4.2025 09:00:00 CEST | Press release
With the introduction of the VIO® 3n, Erbe Elektromedizin GmbH expands its established VIO® 3 family with a new generation of electrosurgical generators, specifically tailored to different medical specialties and procedural requirements. The portfolio is further enhanced by the VIO® seal, the first VIO® generator fully dedicated to bipolar applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425843193/en/ VIO 3n Fire Five configurations for precise surgical and endoscopic applications With over 100 years of experience in electrosurgery, Erbe continues to innovate with the introduction of five new VIO® 3n configurations: Fire, Water, Metal, Timber, and Stone. Each configuration is designed to meet the unique demands of different surgical and endoscopic procedures, providing preprogrammed CUT, COAG, and dissection settings that enhance efficiency and reduce complexity. The VIO® 3n features trusted Erbe electrosurgic
Alipay Sees Tap! Users Pass 100 Million, Accelerating Payment and AI Innovations25.4.2025 04:30:00 CEST | Press release
QR-based contactless payment solution simplifies payment, boosts customer engagement. Alipay is focusing on an AI-first strategy and a two-flywheel approach to growth: digital payment and 360° digital connectivity. Alipay Tap!, a QR code-based contactless payment and customer engagement solution introduced by Alipay in China in June 2024, reports today it has won over 100 million users within 11 months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424690776/en/ FamilyMart leverages Alipay Tap! to simplify payments and membership management. Alipay Tap! further simplifies the payment experience for both consumers and merchants compared to the “scan-and-pay” model ubiquitous in China. Users tap their unlocked phone against a merchant’s terminal or an Alipay Tap! Tag, eliminating the need to open an app, scan a code, or click through multiple screens. Data from early adopters show the solution also allows merchants to inte
DNIB.com Reports Internet Has 368.4 Million Domain Name Registrations at the End of the First Quarter of 202524.4.2025 23:37:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the first quarter of 2025 closed with 368.4 million domain name registrations across all top-level domains (TLDs), an increase of 4.2 million domain name registrations, or 1.1%, compared to the fourth quarter of 2024. Domain name registrations also increased by 6.1 million, or 1.7%, year over year. The .com and .net TLDs had a combined total of 169.8 million domain name registrations in the domain name base at the end of the first quarter of 2025, an increase of 0.8 million domain name registrations, or 0.5% compared to the fourth quarter of 2024. The .com and .net TLDs had a combined decrease of 2.6 million domain name registrations, or 1.5%, year over year. As of March 31, 2025, the .com domain name base totaled 157.2 million domain name registrations and the .ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom